Claims for Patent: 6,471,992

Summary for Patent: 6,471,992

Title:	Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
Abstract:	A rapidly dispersing dosage form is described, which releases its active ingredients within a period of less than about ninety seconds. These dosage forms exhibit a three-dimensional shape that is retained for adequate storage but is readily dispersed in the presence of excess moisture. Also disclosed are methods of administration of a medicament and a process for the preparation of rapidly dispersing dosage forms.
Inventor(s):	Yoo; Jaedeok (Philadelphia, PA), Kumar; Sandeep (Trenton, NJ), Monkhouse; Donald C. (Radnor, PA)
Assignee:	Therics, Inc. (Princeton, NJ)
Application Number:	09/027,183
Patent Claims:	1. A pharmaceutical composition for administration to a subject comprising one or more active ingredients and a rapidly dispersing, non-compressed solid matrix including said one or more active ingredients, said matrix having a layered three-dimensional shape with a defined microstructure and comprising a bulk material and a binder, said bulk material comprising a pharmaceutically acceptable compound in particulate form and said binder comprising a pharmaceutically acceptable, substantially water-soluble substance having the capacity to adhere to and bind together the particles of said bulk material, to maintain the three-dimensional shape of said matrix in the absence of moisture and to permit said composition to exhibit hardness and friability characteristics adequate for storage and handling, provided that said three-dimensional shape is disrupted within a time period of less than about ninety seconds upon contact of said composition with moisture, with release of said one or more active ingredients to said subject. 2. The pharmaceutical composition of claim 1 which is further characterized as exhibiting a bulk density ranging from about 150 (mg/mL) to about 1300 (mg/mL). 3. The pharmaceutical composition of claim 2 which is further characterized as exhibiting a porosity ranging from about 10% to about 90% of the dosage form volume. 4. The pharmaceutical composition of claim 1 in which said time period is less than about sixty seconds. 5. The pharmaceutical composition of claim 1 in which said time period is less than about thirty seconds. 6. The pharmaceutical composition of claim 1 in which said time period is less than about fifteen seconds. 7. The pharmaceutical composition of claim 1 having a hardness ranging from about 1.0 kp to about 20 kp. 8. The pharmaceutical composition of claim 1 having a friability of less than about 25%. 9. The pharmaceutical composition of claim 1 in which said bulk material is selected from the group consisting of spray-dried lactose, fructose, sucrose, dextrose, sorbitol, mannitol, xylitol, and microcrystalline cellulose. 10. The pharmaceutical composition of claim 1 in which said binder is selected from the group consisting of arabinogalactan, polyvinylpyrrolidone, sorbitol, mannitol and xylitol. 11. The pharmaceutical composition of claim 1 in which said one or more active ingredients is selected from the group consisting of chloropheniramine maleate, pseudoephedrine hydrochloride, diphenhydramine hydrochloride, doxylamine succinate, dextromethorphan hydrobromide, acetaminophen, or mixtures thereof. 12. The pharmaceutical composition of claim 1 having a three-dimensional shape that is disrupted within said time period upon contact of said composition with moisture found in a subject's body cavity. 13. The pharmaceutical composition of claim 1 in which said bulk material and said binder comprise water-soluble compounds. 14. The pharmaceutical composition of claim 13 in which said bulk material and said binder comprise the same water-soluble compound. 15. The pharmaceutical composition of claim 14 in which said compound comprises polyvinylpyrrolidone. 16. The pharmaceutical composition of claim 1 in which said bulk material comprises spray dried lactose and said binder comprises polyvinylpyrrolidone. 17. A drug delivery vehicle comprising the pharmaceutical composition of claim 1. 18. The drug delivery vehicle of claim 17 which includes a taste masking agent, a salivary gland stimulant, a breathe refresher, or a nasal decongestant. 19. The drug delivery vehicle of claim 17 applied topically on body surface of a subject. 20. The drug delivery vehicle of claim 19 in which said subject is a mammal.